China's Insurance List Just Cracked Open for Two GLP-1 Newcomers

Pfizer's ecnoglutide is a more conventional GLP-1 receptor agonist, but Pfizer's commercial muscle in China gives it distribution advantages that smaller players can only dream about.

The Price You Pay for 1.4 Billion Patients

Getting on China's national formulary is the pharmaceutical equivalent of getting your product into Costco. The volume is enormous, but the buyer has all the leverage.

Historically, drugs that successfully negotiate their way onto the NRDL accept price cuts of 50% to 70% from their original list price. The NHSA uses what's called the "115% rule": their economists calculate a secret target price, and if a manufacturer's best offer exceeds 115% of that number, the negotiation ends immediately. No second chances.

This creates a brutal calculus. You slash your price to gain access to a system covering roughly 95% of China's insured population, or you keep your price and serve a much smaller pool of patients paying out of pocket. Most companies choose volume.

Linda Shu, head of China healthcare research at HSBC Qianhai, offered a measured take. She told Reuters she doesn't expect a significant competitive challenge from Pfizer or Innovent in diabetes specifically, at least not right away. But she noted that if these drugs make the list, their retail prices will be cut to align with public-hospital pricing. Translation: the era of premium GLP-1 pricing in China is getting squeezed from every direction.

A Crowded Room Gets More Crowded

Pfizer and Innovent aren't entering an empty market. GLP-1 drugs from Novo Nordisk and Eli Lilly are already on China's insurance list for type 2 diabetes. Adding two more reimbursed options turns the competitive landscape into something closer to a cage match.

China's GLP-1 market was estimated at roughly $1.5 billion in 2025, and it's growing fast. Analysts project it could surpass $4.5 billion by 2033. Novo Nordisk still leads, but its sales momentum in China is slowing as domestic competitors and new entrants pile in. The company's CFO has publicly acknowledged that "competition is entering more at this point in time."

And the pressure isn't just coming from injectable GLP-1s. Novo Nordisk's semaglutide patent expires in China in 2026, opening the door to biosimilars. Eli Lilly is pushing orforglipron, an oral GLP-1 that could launch in China by late 2026 or early 2027. Hengrui Pharmaceuticals has its own GLP-1 candidates advancing through late-stage trials.

The Volume-vs.-Margin Trap

For Innovent especially, this moment is both a milestone and a tightrope walk. Mazdutide has already been embedded in Chinese expert consensus guidelines for obesity and type 2 diabetes, which strengthens its clinical credibility. Analysts remain bullish: MarketScreener shows a buy consensus from 29 analysts with a target price roughly 36% above current levels.

But the math is tricky. NRDL inclusion transforms a company's revenue profile from "fewer patients at higher prices" to "many more patients at much lower prices." Whether that trade-off is net positive depends entirely on the discount NHSA demands.

Pfizer faces a similar calculation, though with different stakes. Ecnoglutide is one piece of a much larger China portfolio, and the company didn't disclose pricing or specific launch timing for its weight-loss indication. Pfizer can afford to accept aggressive pricing to build market share; for Innovent, the margins matter more because mazdutide is a cornerstone asset.

What Happens Next

The preliminary review is step one in a four-phase process. Between now and November, NHSA will complete expert evaluations, finalize price anchors, and sit down across the table from Pfizer and Innovent for the real negotiation. If both companies accept the terms, their GLP-1s join the formulary on January 1, 2027, and suddenly become accessible to hundreds of millions of Chinese patients covered by basic insurance.

The biggest question isn't whether these drugs are good enough to make the list. The clinical data speaks for itself. The real question is whether Pfizer and Innovent can stomach the price China demands, and whether the volume makes up for what they leave on the table. In China's GLP-1 market, the ticket to the dance floor costs a lot more than it looks.

New Drug Prices Just Dropped for the First Time in Years. Don't Celebrate Yet.

Median launch prices for new drugs dropped more than 40% in 2025, falling to $216,000 from over $370,000 the year before. But before you celebrate, the reason has nothing to do with pharma companies charging less.